ID

29646

Beschreibung

Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Treatment Timetable. Time: Treatment Period 2.

Link

https://clinicaltrials.gov/ct2/show/NCT00318630

Stichworte

Versionen (1)
  1. 10.04.18 10.04.18 - Sarah Riepenhausen
Rechteinhaber

GlaxoSmithKline

Hochgeladen am

10. April 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630

Englisch

Treatment Timetable - Treatment Period 2

1 Formulare  
Investigational Product
Beschreibung

Investigational Product

Alias
UMLS CUI-1
C0304229
Planned Time Point
Beschreibung

e.g., 2 hours

Datentyp

integer

Alias
UMLS CUI [1,1]
C2348792
UMLS CUI [1,2]
C1301732
Date of Dose
Beschreibung

Day Month Year, e.g. 05 JUN 03

Datentyp

date

Alias
UMLS CUI [1,1]
C0178602
UMLS CUI [1,2]
C0011008
Time of Dose
Beschreibung

Hr:Min 00:00 - 23:59 e.g., 10:54

Datentyp

time

Alias
UMLS CUI [1,1]
C0178602
UMLS CUI [1,2]
C0040223
Treatment Confirmation
Beschreibung

Treatment Confirmation

Alias
UMLS CUI-1
C0750484
UMLS CUI-2
C0087111
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
Beschreibung

Treatment Confirmation

Datentyp

text

Alias
UMLS CUI [1,1]
C0750484
UMLS CUI [1,2]
C0087111
If No, record reason(s)
Beschreibung

Reasons for missed treatment

Datentyp

text

Alias
UMLS CUI [1,1]
C1444662
UMLS CUI [1,2]
C0392360
UMLS CUI [1,3]
C0087111
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Treatment Timetable - Treatment Period 2

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Investigational Product
C0304229 (UMLS CUI-1)
Item
Planned Time Point
integer
C2348792 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
Planned Time Point
Code List
Planned Time Point
CL Item
Day 1 (AM) (1)
(Comment:en)
CL Item
Day 1 (PM) (2)
(Comment:en)
CL Item
Day 2 (AM) (3)
(Comment:en)
CL Item
Day 2 (PM) (4)
(Comment:en)
CL Item
Day 3 (AM) (5)
(Comment:en)
CL Item
Day 3 (PM) (6)
(Comment:en)
CL Item
Day 4 (AM) (7)
(Comment:en)
CL Item
Day 4 (PM) (8)
(Comment:en)
CL Item
Day 5 (AM) (9)
(Comment:en)
CL Item
Day 5 (PM) (10)
(Comment:en)
CL Item
Day 6 (AM) (11)
(Comment:en)
CL Item
Day 6 (PM) (12)
(Comment:en)
CL Item
Day 7 (AM) (13)
(Comment:en)
CL Item
Day 7 (PM) (14)
(Comment:en)
CL Item
Day 8 (AM) (15)
(Comment:en)
CL Item
Day 8 (PM) (16)
(Comment:en)
CL Item
Day 9 (AM) (17)
(Comment:en)
CL Item
Day 9 (PM) (18)
(Comment:en)
CL Item
Day 10 (AM) (19)
(Comment:en)
CL Item
Day 10 (PM) (20)
(Comment:en)
CL Item
Day 11 (AM) (21)
(Comment:en)
CL Item
Day 11 (PM) (22)
(Comment:en)
CL Item
Day 12 (AM) (23)
(Comment:en)
CL Item
Day 12 (PM) (24)
(Comment:en)
CL Item
Day 13 (AM) (25)
(Comment:en)
CL Item
Day 13 (PM) (26)
(Comment:en)
CL Item
Day 14 (AM) (27)
(Comment:en)
CL Item
Day 14 (PM) (28)
(Comment:en)
CL Item
Day 15 (AM) (29)
(Comment:en)
CL Item
Day 15 (PM) (30)
(Comment:en)
CL Item
Day 16 (AM) (31)
(Comment:en)
CL Item
Day 16 (PM) (32)
(Comment:en)
CL Item
Day 17 (AM) (33)
(Comment:en)
CL Item
Day 17 (PM) (34)
(Comment:en)
CL Item
Day 18 (AM) (35)
(Comment:en)
CL Item
Day 18 (PM) (36)
(Comment:en)
CL Item
Day 19 (AM) (37)
(Comment:en)
CL Item
Day 19 (PM) (38)
(Comment:en)
CL Item
Day 20 (AM) (39)
(Comment:en)
CL Item
Day 20 (PM) (40)
(Comment:en)
CL Item
Day 21 (AM) (41)
(Comment:en)
CL Item
Day 21 (PM) (42)
(Comment:en)
CL Item
Day 22 (AM) (43)
(Comment:en)
CL Item
Day 22 (PM) (44)
(Comment:en)
CL Item
Day 23 (AM) (45)
(Comment:en)
CL Item
Day 23 (PM) (46)
(Comment:en)
CL Item
Day 24 (AM) (47)
(Comment:en)
CL Item
Day 24 (PM) (48)
(Comment:en)
CL Item
Day 25 (AM) (49)
(Comment:en)
CL Item
Day 25 (PM) (50)
(Comment:en)
CL Item
Day 26 (AM) (51)
(Comment:en)
CL Item
Day 26 (PM) (52)
(Comment:en)
CL Item
Day 27 (AM) (53)
(Comment:en)
CL Item
Day 27 (PM) (54)
(Comment:en)
CL Item
Day 28 (AM) (55)
(Comment:en)
CL Item
Day 28 (PM) (56)
(Comment:en)
Date of Dose
Item
Date of Dose
date
C0178602 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Time of Dose
Item
Time of Dose
time
C0178602 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
Item Group
Treatment Confirmation
C0750484 (UMLS CUI-1)
C0087111 (UMLS CUI-2)
Item
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
text
C0750484 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
Treatment Confirmation
Code List
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
CL Item
yes (Y)
CL Item
no (N)
Reasons for missed treatment
Item
If No, record reason(s)
text
C1444662 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video